Targeted diagnosis, more precise therapy: results of MR fusion biopsy at the Budapest Péterfy Sándor Street Hospital and Outpatient Clinic
DOI: 10.22591/magyurol.2025.2.bartekv.46
Authors:
Bartek Virág dr.1, Berta Tibor dr.1, Altenni Mohammed dr.1,
Lajos Márton dr.1, Volford Gábor dr.2, Márványkövi Fanni Magdolna dr.1,
Beöthe Tamás dr.1, Buzogány István dr.1
1Budapesti Péterfy Sándor Utcai Kórház-Rendelőintézet, Budapest (osztályvezető: Buzogány István dr.)
2Affidea Magyarország Kft.
Summary
Introduction: Prostate cancer affects approximately one in eight men during their lifetime. The gold standard for diagnosis is a biopsy, which can be performed using either the transrectal or transperineal approach. With advances in radiology, in addition to traditional “mapping” biopsies, MRI-ultrasound fusion techniques are increasingly being used. Prostate lesions identified on MRI can be categorized from 1 to 5 based on the PI-RADS (Prostate Imaging-Reporting and Data System) criteria. These categories reflect the likelihood that a lesion is clinically significant (defined as ISUP grade ≥2 or Gleason score ≥3+4).
Material and methods: Between 2019 and 2024, a total of 478 MRI fusion-guided prostate biopsies were performed at the Urology Department of Péterfy Sándor Street Hospital and Clinic. Of these, 368 cases were included in the analysis; cases lacking baseline PSA data were excluded.
Results: Age 68.33±7.49, PSA 12.38±11.76. Prostate carcinoma was confirmed in 247 cases, negative results were obtained in 121 cases. In 47 cases, a positive sample was obtained after a previous negative biopsy. In 1 case, a positive sample was taken from a PI-RADS-3, in 17 cases, PI-RADS-4, and in 29 cases, PI-RADS-5 nodule.
Conclusion: MRI fusion-guided prostate biopsy enhances the early detection of clinically significant prostate tumours. This technique facilitates earlier and more accurate histological diagnosis, allowing timely initiation of appropriate therapy and ultimately improving patient outcomes and survival rates.